SOPHiA GENETICS Partners with Jessa Ziekenhuis to Enhance Precision Oncology in Belgium
SOPHiA GENETICS, a leading cloud-native healthcare technology company, announced a major partnership with Jessa Ziekenhuis in Hasselt, Belgium, aimed at enhancing genomic testing and oncology research for cancer patients throughout the country. This collaboration will see the implementation of SOPHiA GENETICS' fully automated, cloud-native solutions tailored to oncology needs, allowing Jessa Ziekenhuis to unify workflows, accelerate insights, and improve patient care. The partnership is expected to reduce hands-on time by 30-50%, decrease costs by up to 25%, and speed up testing turnaround times. This initiative marks an important investment in personalized medicine, supporting advanced oncological care and research in Belgium.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE65965) on September 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.